IQVIA is a global provider of clinical research services, healthcare data, advanced analytics, and technology solutions that help life sciences companies accelerate the development and delivery of innovative medicines. By combining deep scientific expertise with extensive healthcare data and AI-powered insights, IQVIA supports pharmaceutical and biotechnology companies across the drug development lifecycle—from discovery and clinical trials to regulatory approval and commercialization.

In this conversation with Contract Pharma, Elizabeth Allen, PhD., Vice President, Early Phase Center of Excellence, Raymond Cook, Global Head, Early Phase Center of Excellence, and Janet Rosasco, Senior Therapeutic Strategy Lead Director, highlight IQVIA’s capabilities in early clinical development. Specifically, they explore how IQVIA helps biotechs navigate uncertainty, what it means to be a successful strategic development partner, how the company ensures a seamless transition from early- to late-phase trials and more.

Contract Pharma: With increasing scientific complexity—such as precision medicine, rare diseases, and cell/gene therapies—what shifts is IQVIA seeing in early-phase design and execution requirements?

Elizabeth Allen: As scientific complexity increases, early-phase study designs have shifted from traditional safety- and PK-focused Phase I studies toward integrated, translational studies designed to generate accelerated go/no-go evidence. Early-phase studies increasingly incorporate adaptive and hybrid designs, enabling…